Omalizumab
Indication
Chronic spontaneous urticaria (NICE TA339)
NICE TA339 - Omalizumab for previously treated chronic spontaneous urticaria
Red
Brand:
Xolair®
Nice TA:
339
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Skin
Background
Omalizumab is recommended as an option as add‑on therapy for treating severe chronic spontaneous urticaria in adults and young people aged 12 years and over only if:
- the severity of the condition is assessed objectively, for example, using a weekly urticaria activity score of 28 or more
- the person’s condition has not responded to standard treatment with H1‑antihistamines and leukotriene receptor antagonists
- omalizumab is stopped at or before the fourth dose if the condition has not responded
- omalizumab is stopped at the end of a course of treatment (6 doses) if the condition has responded, to establish whether the condition has gone into spontaneous remission, and is restarted only if the condition relapses
- omalizumab is administered under the management of a secondary care specialist in dermatology, immunology or allergy
- the company provides omalizumab with the discount agreed in the patient access scheme.